CD79A and COVID-19: Oral plant-based platforms have also reached late-stage development; for instance, the Nicotiana-derived VLP vaccine Covifenz successfully completed Phase 3 trials against COVID-19, and MucoRice-CTB showed strong mucosal IgA induction in early clinical testing for cholera.